RecruitingPhase 4NCT07193849
Zinc Oxide VS MEBO
Impact of Using Zinc Oxide Versus Moist Exposed Wound Ointment (MEBO) in Treatment of Second Stage Pressure Ulcer: A Randomized Control Clinical Trial
Sponsor
King Abdullah Medical City
Enrollment
76 participants
Start Date
Dec 31, 2023
Study Type
INTERVENTIONAL
Summary
randomize control trial to evaluate the efficacy of using zinc oxide versus moist exposed wound ointment in treatment of second stage pressure ulcer.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Willing to participate.
- KAMC cases in medical ward, neuroscience ward, and intensive care unit.
- Newly cases diagnosed with second stage pressure ulcer according to the European pressure ulcer advisory panel/national pressure ulcer advisory panel (NPUAP) guidelines.
Exclusion Criteria9
- Not consenting to participate
- Patients with suspected hypersensitivity reactions to any of the topical formulation's ingredients.
- Either a category III or IV pressure ulcer.
- Evidence of deep tissue injury (exudative drainage, purple or maroon localized area of discolored intact skin or blood-filled blister due to pressure damage).
- Signs of wound infection (pus draining from the ulcer, a foul-smelling odour, tenderness, heat and increased redness in the surrounding skin and fever).
- Patients who undertaking other therapies that could affect healing, such as corticosteroids, radiation therapy, or chemotherapy for cancer.
- Heavy smoking (more than 20 cigarettes a day).
- Concomitant chronic disease (e.g., diabetes mellitus or frank vascular disease such as Buerger's disease).
- Patients who unable to continue the study because of death, discharge, or change in the care setting.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMEBO Wound Ointment
both are used for second pressure ulcer
DRUGzinc oxide
both are used to treat second degree pressure ulcer but with no superiority
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07193849